AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03000608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAN021 Serum
Description: SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
Study NCT03068533 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: use of strontium acetate toothpaste
Description: use of strontium acetate toothpaste to relieve hypersensitivity
Study NCT01190514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained release
Description: Two tablets of 25 mg, single administration, under fed condition
Study NCT01190514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained release
Description: One tablet of 50 mg, single administration, under fed condition
Study NCT01190514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained release
Description: Two tablets of 25 mg, single administration, under fast condition
Study NCT01190514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desvenlafaxine succinate sustained release
Description: One tablet of 50 mg, single administration, under fast condition
Study NCT04628819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Babybiane Imedia or placebo
Description: Both the investigational product as well as the placebo will be administered once daily, diluted in a nursing bottle or a glass of water or cold milk, or mixed with a food suitable for the child. It may be diluted in oral rehydration solution and is to be taken preferably before a meal. Both preparations (BABYBIANE® Imedia and placebo) will have similar consistency and taste. A supplementation unit will contain 7 packs of either products, one per supplementation day.
Study NCT04628819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Babybiane Imedia or placebo
Description: Both the investigational product as well as the placebo will be administered once daily, diluted in a nursing bottle or a glass of water or cold milk, or mixed with a food suitable for the child. It may be diluted in oral rehydration solution and is to be taken preferably before a meal. Both preparations (BABYBIANE® Imedia and placebo) will have similar consistency and taste. A supplementation unit will contain 7 packs of either products, one per supplementation day.
Study NCT01327859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prior Donepezil 5mg
Description: Received 5 mg donepezil once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
Study NCT01327859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prior Donzepezil 10mg
Description: Received 10 mg donepezil once daily during the preceding double-blind study, E2020-G000-316 . Received open-label 5 or 10 mg donepezil during the present study.
Study NCT01327859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prior Placebo
Description: Received placebo once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
Study NCT02054988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: caffeine
Description: After 5 day coffee wash-out period, patients were randomly assigned to caffeine for 10 days. At baseline: 2 cups of coffee consecutively after 5 hour by clopidogrel or prasugrel intake. Afterwards, 3 cups of coffee daily for 10 days.~Platelet reactivity (expressed as P2Y(12) reaction units (PRU) by the point-of-care VerifyNow assay \[Accumetrics, San Diego, California\]) was measured at baseline and after 10-days of coffee intake.
Study NCT02054988 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: not caffeine
Description: evaluate the platelet reactivity after 10 days of no caffeine intake
Study NCT04257591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hamstring strengthening
Description: A progressive and individualized hamstring strengthening protocol
Study NCT01597453 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle counseling
Description: Ultrasound examinations of carotid arteries, aorta abdominalis, femoral arteries and lifestyle counseling
Study NCT04390022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Single dose of STROMECTOL® tablets at 400mcg/kg
Study NCT04390022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets will not match ivermectin but they will be administered by staff not involved in the clinical care.
Study NCT02619149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin-tazobactam combination product
Description: Piperacillin-Tazobactam (extended-spectrum, beta-lactamase inhibitor) iv peroperatively as prophylaxis
Study NCT02619149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline iv as placebo control
Study NCT02068209 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: patients will receive Tramadol 50mg orally 1 hour before outpatient hysteroscopy.
Study NCT02068209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: patients will receive a placebo 1 hour before outpatient hysteroscopy
Study NCT03525288 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PSMA -PET/CT simulation
Description: * PET/CT simulation.~* If no additional lesions detected: RT as planned per standard care.~* If PSMA-PET/CT imaging consistent with oligometastases (1-5 lesions): all lesions must be treated with definitive RT.~* If PSMA-PET/CT imaging consistent with widely metastatic disease (>5 lesions): treatment of all detected disease with RT is not recommended, but treatment of the primary site as initially planned is encouraged.
Study NCT03525288 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard-care simulation
Description: No PSMA-PET/CT as part of RT treatment planning.
Study NCT04214600 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Patients in the CBT intervention group will receive four educational sessions for 30-45 minutes on one to one basis every two weeks during patients' regular follow up visits. The visits will be scheduled depending on the patient's availability. The sessions will be delivered by a trained physician. The sessions will include:~Session 1: Dealing with thoughts of sadness and depression Session 2: Dealing with thoughts of anxiety and stress Session 3: Dealing with anger Session 4: Enhancement of coping and problem-solving skills
Study NCT00842270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB1010
Description: 3 mg/kg/day
Study NCT00842270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB1010
Description: 4,5 mg/kg/day
Study NCT00842270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB1010
Description: 6 mg/kg/day
Study NCT00842270 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo to AB1010 dosages
Study NCT03013660 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Limited Financial Support
Description: Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment.
Study NCT05316415 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acemaşiran Music Group
Description: Agreeing to participate in the study Knowing Turkish and being literate Having been hospitalized for bed rest for at least 5 days. Having a gestational age of 28 to 36 weeks Being hospitalized due to at least one of the diagnoses including hypertensive diseases, diabetes mellitus, preterm labor, placenta previa, cervical insufficiency, or premature rupture of the membrane
Study NCT01621113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalfampridine
Description: Dalfampridine 10 mg tablet, twice-daily, for 10 weeks
Study NCT01621113 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet, twice daily, for 10 weeks.
Study NCT03274960 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Griess,
Description: Experimental: Griess, Culture and antibiotic Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
Study NCT03719170 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPI De-prescribing Program
Description: The PPI de-prescribing program includes alerts to clinical pharmacy specialists and primary care providers informing them of individual patients scheduled for upcoming primary care visits who meet criteria for PPI de-prescription; activation of clinical pharmacy specialists; education of primary care providers; and patient education.
Study NCT02708719 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Pulmonary rehabilitation
Description: Inpatient pulmonary rehabilitation has a duration of 3 weeks. This multimodal program consists of exercise training, breathing therapy, medical council, education and psychological support.
Study NCT05025202 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric exercise training
Description: A form of exercise involving static contraction against a wall, sustained for 2 minutes x4 sets per session. 3 sessions a week were required. The intensity was designed to achieve 95% of the participants maximum heart rate.
Study NCT05025202 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Isometric exercise training
Description: A form of exercise involving static contraction against a wall, sustained for 2 minutes x4 sets per session. 3 sessions a week were required. The intensity was designed to achieve 95% of the participants maximum heart rate.
Study NCT00003657 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00003657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Study NCT00003657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT00003657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Study NCT00003657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Study NCT00003657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT03000608 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SAN021 Placebo
Description: SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
Study NCT02091648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Can Cope Intervention
Description: Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques.
Study NCT02091648 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education Intervention
Description: This group will receive the standard American Lung Association (ALA)Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute's recommendations for asthma education.
Study NCT01633983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 7.5 mg per week p.o. escalating up to 15 mg per week
Study NCT01633983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delayed treatment
Description: Methotrexate 7.5 mg per week per os escalating to 15 mg per week
Study NCT01600521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs
Description: The comparisons of the efficacy and safety of the following treatments for rheumatoid arthritis: paeoniflorin (PAE) + Cervus and Cucumis polypeptide injection (CCPI), methotrexate (MTX) + leflunomide (LEF), and MTX + LEF + CCPI.
Study NCT03448120 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Six needled will be inserted in six already defined acupoints along the non-dominant upper limb for a period of 30 minutes.
Study NCT03448120 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Six needles will be inserted in six predefined points along the volunteers non-dominant biceps brachialis for 30 minutes.
Study NCT02833532 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volus/Powerfill
Description: Maximum: 22ml
Study NCT02833532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Volus/Powerfill
Description: Maximum: 22ml
Study NCT00118755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 850 mg/m\^2 po bid on Days 1-14 of each 3-week cycle
Study NCT00118755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m\^2 IV on Day 1 of each 3-week cycle
Study NCT00118755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 7.5 mg/kg IV on Day 1 of each 3-week cycle
Study NCT00118755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: 1500 mg/m\^2 po bid on Days 1-7 of each 2-week cycle
Study NCT00118755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 85 mg/m\^2 IV on Day 1 of each 2-week cycle
Study NCT00118755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 5 mg/kg IV on Day 1 of each 2-week cycle
Study NCT00686725 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Study NCT00686725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT00686725 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Study NCT00686725 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT03237351 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid therapy
Description: Conventional therapy group: conventional arterial blood pressure monitoring. Low value of PPV group and high value of PPV group:pulse pressure variation monitoring with arterial blood pressure monitoring.
Study NCT03237351 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluid therapy
Description: Conventional therapy group: conventional arterial blood pressure monitoring. Low value of PPV group and high value of PPV group:pulse pressure variation monitoring with arterial blood pressure monitoring.
Study NCT00292162 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: isolation of the pulmonary veins with radiofrequency ablation (RFA)
Study NCT00292162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril
Description: Evidence based treatment for heart failure. Dose and type will depend on patient tolerability.
Study NCT00292162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol
Description: Evidence based treatment for heart failure. Dose and type will depend on patient tolerance.
Study NCT00292162 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldosterone Antagonists - spironolactone
Description: Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.
Study NCT02445950 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-aided phone wellness counselling
Description: The intervention provides phone wellness counselling with the help of web-based interventions, digital profiling and suggestion tool in occupational health.
Study NCT02445950 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone wellness counselling
Description: The intervention provides phone wellness counseling in occupational health.
Study NCT02118558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Study NCT02118558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard prophylactic therapy
Description: administration of antibiotics before the first incision, keeping the surgery field sterile and performing several rinsing
Study NCT02490553 — intervention group
Intervention type: OTHER
Intervention: heteroevaluation scale by a nurse or doctor
Study NCT01386788 — intervention group
Intervention type: OTHER
Intervention: There is no intervention planned (observational)
Description: No intervention foreseen
Study NCT02783664 — intervention group
Intervention type: OTHER
Intervention: Questionnaires to Evaluate Anxiety Related to Genetic Testing
Description: A health team member will outline the study parameters to the patient prior to the genetic counseling visit.~Visit 1: At the genetic counseling appointment (prior to counseling) patients will receive the following: the State-Trait Anxiety Inventory (STAI) for Adults) to measure baseline anxiety, the Health Anxiety Inventory (HAI) to measure baseline health anxiety, the modified Cancer Worry Scale (CWS) to measure baseline cancer worry in addition to some additional questions about the patient's background. The patient will complete the questionnaires privately and then return them to the genetic counselor.~Follow-up: One week following disclosure of genetic testing results (3 weeks after the initial appointment), a research team member will call the patient and administer the HAI and CWS over the phone. This will be repeated at 5 weeks, 3 months, and 6 months after initial visit.~Time to take initial surveys: 15-20 minutes total. Follow-up calls: 10-15 minutes total.
Study NCT02863471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 milligram (mg)/square meters (m2) body surface 60 minutes (min) intraperitoneal hyperthermic lavage
Study NCT02938260 — intervention group
Intervention type: DRUG
Intervention: Metoprolol vs Diltiazem
Study NCT00898898 — intervention group
Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies
Study NCT02029846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: traditional drugs only
Study NCT02029846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Incretin-Based Treatment
Description: incretin-based drugs
Study NCT03060460 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound guided sheath insertion
Description: ultrasound is used routinely for sheath insertion
Study NCT01689337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sprifermin (AS902330)
Description: Sprifermin (AS902330) will be administered at a dose of 30 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
Study NCT01689337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sprifermin (AS902330)
Description: Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
Study NCT01689337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to Sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
Study NCT02389608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: The active tDCS and placebo will be applied to the primary motor cortex (M1) and FES active and placebo will be applied to the anterior tibial muscle (TA).
Study NCT02389608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Study NCT02389608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation
Study NCT03169504 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Feishu (BL13), Dazhui (DU14) and Fengmen (BL12) will be selected as main acupoints. There are four groups of acupoints: Taiyuan (LU9) and Zusanli (ST36) for Qi deficiency of the lung ZHEGN, Taiyuan (LU9), Pishu (BL20) and Zusanli (ST36) for Qi deficiency of the lung and spleen ZHEGN, Taiyuan (LU9), Shenshu (BL23) and Zusanli (ST36) for Qi deficiency of the lung and kidney ZHEGN, and Gaohuang (BL43), Shenshu (BL23), Taixi (KI3) and Guanyuan (RN4) for Qi and Yin deficiency of the lung and kidney ZHEGN. Besides, acupoints for specific symptoms will also be considered. Hwato Sterile Acupuncture Needles For Single Use (Hwato®, Suzhou Hua Tuo Medical Instruments Co., Ltd.) size in 0.30\*25 mm, 0.30\*40 mm or 0.30\*50 mm will be used 3 times weekly for 12 weeks.